Sugi Predict

Sugi Predict / Targets / OGA

OGA

Protein O-GlcNAcase · O60502 · OGA on Sugi Atlas →

34,671 patent compounds predicted against OGA, 14,641 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Allosamizoline Allosamizoline (SCHEMBL691526) 1.00 18/20
SCHEMBL460638 SCHEMBL460638 0.56 18/20
SCHEMBL1000190 SCHEMBL1000190 0.52 17/20
SCHEMBL999948 SCHEMBL999948 0.50 17/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1000424) 0.50 17/20
SCHEMBL1000090 SCHEMBL1000090 0.53 16/20
SCHEMBL998939 SCHEMBL998939 0.52 16/20
SCHEMBL1002061 SCHEMBL1002061 0.52 16/20
SCHEMBL998067 SCHEMBL998067 0.52 15/20
SCHEMBL999281 SCHEMBL999281 0.52 15/20
SCHEMBL1002250 SCHEMBL1002250 0.51 15/20
SCHEMBL1000425 SCHEMBL1000425 0.50 15/20
SCHEMBL1002565 SCHEMBL1002565 0.49 15/20
SCHEMBL1000163 SCHEMBL1000163 0.52 13/20
SCHEMBL460094 SCHEMBL460094 0.53 12/20
SCHEMBL668693 SCHEMBL668693 0.48 12/20
SCHEMBL657716 SCHEMBL657716 0.66 11/20
SCHEMBL890101 SCHEMBL890101 0.55 11/20
SCHEMBL610456 SCHEMBL610456 0.41 11/20
SCHEMBL83122 SCHEMBL83122 0.50 10/20

Clinical trials — most relevant to OGA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease PHASE2COMPLETED
Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery PHASE2COMPLETED
Diabetic Retinopathy Sulodexide Study PHASE2COMPLETED
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy PHASE2RECRUITING
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer PHASE2COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases PHASE1COMPLETED
NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM PHASE1WITHDRAWN
The Effect of Acute Lysine Administration on α-aminoadipic Acid PHASE1COMPLETED
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children nanRECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children nanRECRUITING
Evaluation of a Novel PET Radioligand to Image OGA nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain nanUNKNOWN
Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects nanUNKNOWN
Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism nanCOMPLETED
Mucin Glycosylating Enzymes in Head and Neck Cancers nanUNKNOWN
Omega-3 Fatty Acids Supplementation and Atherothrombotic Biomarkers in Type 2 Diabetes and Cardiovascular Disease. nanCOMPLETED
The Effect of Raising Ketones Directly With MCT Oil on Inflammation in Healthy Young Adults nanCOMPLETED
The Natural History of Alpha-Mannosidosis nanCOMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain nanCOMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers nanUNKNOWN
Effects of a Dietary Supplement on Collagen Production and Evaluation of Its Regenerative and Anti-Ageing Propertiess nanCOMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Advanced Glycation End Products and Dietary Intervention in Polycystic Ovary Patients nanUNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a OGA binder may also engage these)

ProteinNameSimilarity
Q8VIJ5 — 1.000 Q8VIJ5 →
Q9EQQ9 — 1.000 Q9EQQ9 →
KDM5B Lysine-specific demethylase 5B 0.994 landscape →
DHX29 ATP-dependent RNA helicase DHX29 0.993 landscape →
KDM5D Lysine-specific demethylase 5D 0.993 landscape →
KAT8 Histone acetyltransferase KAT8 0.992 landscape →
Q62240 — 0.991 Q62240 →
PPP2R5D Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform 0.991 landscape →
Q5XUN4 — 0.991 Q5XUN4 →
Q7Z3E5 — 0.991 Q7Z3E5 →
Q5XI06 — 0.991 Q5XI06 →
Q28653 — 0.991 Q28653 →
Q5XHF8 — 0.991 Q5XHF8 →
A0JMD0 — 0.991 A0JMD0 →
Q8BMD7 — 0.991 Q8BMD7 →
Q7Z401 — 0.990 Q7Z401 →
P41230 — 0.990 P41230 →
Q5F3R2 — 0.990 Q5F3R2 →
A8E7C5 — 0.990 A8E7C5 →
Q9Y2H2 — 0.990 Q9Y2H2 →
Q14149 — 0.990 Q14149 →
Q3UXZ9 — 0.990 Q3UXZ9 →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.990 landscape →
Q1LYM3 — 0.990 Q1LYM3 →
A3KMI0 — 0.990 A3KMI0 →
Q5PQS3 — 0.990 Q5PQS3 →
F4J8C6 — 0.989 F4J8C6 →
Q8BX57 — 0.989 Q8BX57 →
Q8C042 — 0.989 Q8C042 →
Q10MI0 — 0.989 Q10MI0 →